Recently there has been a significant resurgence in the use of gene and cell therapies thanks to improving efficiencies and safety of these methodologies. As we described in last week's issue of BioWorld Insight, with a number of gene therapies advancing into later-stage trials, the field has begun to attract significant amounts of both private and public capital investments once again.